Related Experiment Video
Updated: Jul 4, 2025
Sub-acute Cerebral Microhemorrhages Induced by Lipopolysaccharide Injection in Rats
Published on: October 17, 2018
Minocycline alleviates LPS-induced cognitive dysfunction in mice by inhibiting the NLRP3/caspase-1 pathway
Fenfang Zhan1,2, Yao Dong1,2, Lanqian Zhou1,2
1Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Background:
Growing experimental evidence indicates that cognitive impairment is linked to neuroinflammation. Minocycline (MINO), an antibiotic known for its anti-inflammatory, has shown promise in alleviating cognitive impairment. Nonetheless, the exact mechanism through which MINO improves cognitive impairment is not yet understood.
Methods:
A neuroinflammatory model was establish by utilizing lipopolysaccharide. The assessment of mice's cognitive and learning abilities was conducted through the MWM and Y-maze tests. The evaluation of hippocampal neuronal injury and microglial activation were achieved by performing HE staining and IHC, respectively. To evaluate BV2 cell viability and apoptosis, the CCK-8 and Hoechst 33342/PI staining assays were employed. In order to assess the protein and RNA expression levels of NLRP3, caspase-1, IL-1β, IL-18, Iba-1, and Bcl2/Bax, WB and RT-qPCR were utilized. Additionally, the inhibitory effect of MINO on apoptosis by targeting the NLRP3/caspase-1 pathway was investigated using Nigericin.
Results:
MINO was effective in reducing the time it took for mice to escape from the test, increasing the number of platforms they crossed, and mitigating damage to the hippocampus while also suppressing microglial activation and the expression of Iba-1 in a neuroinflammatory model caused by LPS. Furthermore, MINO improved the viability of BV2 cell and reduced apoptosis. It also had the effect of reducing the expression levels of NLRP3/Caspase-1, IL-1β, IL-18, and BAX, while upregulating the expression of Bcl2. Additionally, MINO was found to downregulate the NLRP3 expression, which is specifically activated by nigericin.
Conclusion:
The protective effect of MINO relies on the crucial involvement of the NLRP3/caspase-1 pathway.
Insights
Minocycline (MINO) reduces neuroinflammation and cognitive impairment in mice by inhibiting the NLRP3/caspase-1 pathway. This antibiotic improves learning and memory while protecting hippocampal neurons and reducing microglial activation.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Cognitive impairment is increasingly linked to neuroinflammation.
- Minocycline (MINO), an anti-inflammatory antibiotic, shows potential for alleviating cognitive deficits.
- The precise mechanisms by which MINO exerts its cognitive benefits remain unclear.
Purpose of the Study:
- To elucidate the neuroprotective and cognitive-enhancing mechanisms of Minocycline (MINO).
- To investigate the role of the NLRP3/caspase-1 inflammasome pathway in MINO's therapeutic effects.
- To evaluate MINO's impact on neuroinflammation, neuronal injury, and apoptosis in a mouse model.
Main Methods:
- Established a neuroinflammatory mouse model using lipopolysaccharide (LPS).
- Assessed cognitive and learning functions via the Morris Water Maze (MWM) and Y-maze tests.
- Utilized HE staining, IHC, CCK-8, Hoechst 33342/PI staining, Western blot (WB), and RT-qPCR to evaluate cellular changes and molecular markers, including NLRP3, caspase-1, IL-1β, IL-18, Iba-1, and Bcl2/Bax.
Main Results:
- MINO treatment significantly improved cognitive performance in LPS-induced neuroinflammation.
- MINO reduced hippocampal neuronal injury, suppressed microglial activation (Iba-1 expression), and decreased apoptosis in BV2 cells.
- MINO downregulated the expression of NLRP3, caspase-1, IL-1β, IL-18, and Bax, while upregulating Bcl2, indicating inhibition of the NLRP3/caspase-1 pathway.
Conclusions:
- Minocycline (MINO) demonstrates significant neuroprotective and cognitive-enhancing effects.
- The therapeutic benefits of MINO are critically dependent on the inhibition of the NLRP3/caspase-1 inflammasome pathway.
- MINO represents a promising therapeutic agent for cognitive impairments associated with neuroinflammation.
